We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Proof of concept of the preventive efficacy of high-dose recombinant mono-allergen immunotherapy in atopic dogs sensitized to the Dermatophagoides farinae allergen Der f 2.
- Authors
Olivry, Thierry; Paps, Judy S.; Dunston, Stanley M.
- Abstract
Background Allergen immunotherapy is currently the only intervention proposed to specifically prevent clinical flares after allergen challenges. The low molecular weight Der f 2 (Df2) is a major allergen in Japanese dogs sensitized to Dermatophagoides farinae house dust mites. Objectives Pilot, blinded, placebo-controlled experiment testing the efficacy of subcutaneous immunotherapy ( SCIT) with high doses of recombinant Df2 conjugated to the maltotriose pullulan (r Df2-P). Methods Eight Maltese beagle atopic dogs were sensitized to r Df2 then randomized to SCIT with r Df2-P (six dogs) or placebo (two). The immunotherapy consisted of six weekly injections of increasing doses (0.1-10.0 μg) of r Df2-P followed by four monthly injections of 10 μg of this allergen. Epicutaneous r Df2 challenges, r Df2-specific IgE serology and intradermal reactivity, as well as serum cytokine level measurements, were performed throughout the study. Results Subcutaneous injections of placebo did not alter the cutaneous reactivity after r Df2 challenge, while that of the dogs treated with r Df2-P SCIT disappeared in five of six dogs (83%) and was reduced in one of six (17%). During SCIT maintenance, skin lesion scores were significantly lower in dogs receiving SCIT compared to those treated with placebo. This clinical improvement was accompanied by a concurrent, yet not significant, decrease in r Df2-specific IgE serology and immediate intradermal reactivity. Cytokine serum levels were inconclusive. There were no adverse events seen with r Df2-P SCIT. Conclusions and clinical importance The new mono-allergen SCIT appears safe and effective for reducing skin lesions after allergen challenges; it deserves further testing in dogs with spontaneous atopic dermatitis.
- Subjects
ALLERGENS; IMMUNOTHERAPY; DERMATOPHAGOIDES; CYTOKINES; SEROLOGY; ATOPIC dermatitis
- Publication
Veterinary Dermatology, 2017, Vol 28, Issue 2, p183
- ISSN
0959-4493
- Publication type
Article
- DOI
10.1111/vde.12395